RADIOPHARMACEUTICALS BASED ON ANTAGONISTS OF CHEMOCINE RECEPTOR CXCR4 IN DIAGNOSTICS AND TREATMENT OF ONCOLOGICAL DISEASES.

The review is devoted to the use of a new class of radiopharmaceuticals (RPs) - chemokine receptor ligands - in oncological practice. The chemokine receptor CXCR4 is of particular interest as a molecular target in the diagnosis and treatment of malignant tumors, as it plays an important role in carcinogenesis. By interacting with the chemokine CCXL12, it activates cell signaling pathways that affect tumor cell proliferation, angiogenesis, metastasis growth, and apoptosis inhibition.

RADIOPHARMACEUTICALS BASED ON FIBROBLAST ACTIVATION PROTEIN INHIBITORS IN ONCOLOGICAL PRACTICE.

The review is devoted to the application of the new perspective class of radionuclide tracers, based on inhibitors of the fibroblast activation protein (FAP), which is a marker of cancer-associated fibroblasts of microenvironment of most malignant tumors. FAP inhibitors (FAPI) can be labeled by a wide spectrum of radionuclides, which can provide both radionuclide diagnostics and radionuclide therapy. It was showed, that the diagnostic efficacy of FAPI positron emission tomography/computed tomography (PET/CT) in various cancers is similar to 18F-fluorodesoxyglu-cose-PET/CT or superior.

DOSE RELATIONSHIP DURING RADIOABLATION OF THYROID RESIDUAL IN PATIENTS WITH THYROID DIFFERENTIATED CANCER.

Objective: to study relationship between the focal adsorbed doses (FAD) in the residual thyroid tissue (RTT) atradioiodine therapy (RIT) in patients with differentiated thyroid cancer (DTC) and efficacy of radioablation (RA).

Materials And Methods: FAD in RTT in 221 patients aged 25-74 years were analyzed. Scintigraphic investigations were executed using gamma-camera «МВ 9200» and single photon emission tomograph «Е.

[The efficacy of radio-iodine-therapy in patients with differentiated form cancer of thyroid gland in various after thyroidectomy].

Results of treatment of 376 patients, ageing 18-76 yrs, were analyzed to investigate the radioiodine therapy (RITH) efficacy for the thyroid differentiated cancer depending on the term of its conduction after the operation. In patients with the thyroid gland residual tissue (THGRT) only the first course of RITH efficacy was 82.6-96.